Opportunities In Personalised Medicine Industry On Prescient’s Radar

Clinical stage oncology company, Prescient Therapeutics Limited (ASX: PTX) is engaged in developing personalised medicines to treat a range of challenging cancers. The company...

Journey of Prescient Therapeutics in 2019

Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company that works on mutation causing cancer. The existing product portfolio of the company includes...

Prescient Therapeutics’ Cancer Trials Backed By A Robust Product Portfolio

Clinical stage oncology company Prescient Therapeutics Limited (ASX: PTX) is in the process of developing a breakthrough to traditional therapies by its novel drug...

Prescient Therapeutics starts Phase 1b clinical trial of its unique inhibitor PTX-100

On 11 July 2019, Prescient Therapeutics Limited (ASX: PTX) announced the commencement of a Phase 1b trial of its second targeted anti-cancer drug PTX-100...

Prescient Therapeutics’ drug candidates addressing the mutations causing cancer

Clinical-Stage oncology company, Prescient Therapeutics Limited (ASX: PTX) bases the foundation of its business model on the ground-breaking technology that addresses the mutations causing...

Latest News

Editorial

Quick Look at Stock Screening And 8 Tech Stocks for 2019/2020

Screening of stocks is a process in which an investor “screens” stocks based on specific criteria which would help the investor build a portfolio...

EIA Forecast Bring More Shock Waves For ASX-listed Oil & Gas Explorers

The United States Energy Information Administration (or EIA) did not sound very optimistic over the crude oil future in its September energy outlook, which...